90 related articles for article (PubMed ID: 3996812)
1. [Urinary prostaglandins in the hepatorenal syndrome of cirrhotic patients: role of thromboxane A2 and an imbalance of precursor polyunsaturated fatty acids].
Parelon G; Mirouze D; Michel F; Crastes de Paulet P; Chaintreuil J; Crastes de Paulet A; Michel H
Gastroenterol Clin Biol; 1985 Apr; 9(4):290-7. PubMed ID: 3996812
[TBL] [Abstract][Full Text] [Related]
2. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors.
Zipser RD; Radvan GH; Kronborg IJ; Duke R; Little TE
Gastroenterology; 1983 Apr; 84(4):697-703. PubMed ID: 6572162
[TBL] [Abstract][Full Text] [Related]
3. Arachidonic acid derivatives and renal function in liver cirrhosis.
Laffi G; La Villa G; Pinzani M; Marra F; Gentilini P
Semin Nephrol; 1997 Nov; 17(6):530-48. PubMed ID: 9353864
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin precursor fatty acids in cirrhosis with ascites: effect of linoleic acid infusion in functional renal failure.
Rimola A; Ginés P; Cusó E; Camps J; Gaya J; Arroyo V; Rodés J
Clin Sci (Lond); 1988 Jun; 74(6):613-9. PubMed ID: 3135142
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
6. Effect of spironolactone on renal prostaglandin excretion in patients with liver cirrhosis and ascites.
Medina JF; Prieto J; Guarner F; Quiroga J; Milazzo A
J Hepatol; 1986; 3(2):206-11. PubMed ID: 3466948
[TBL] [Abstract][Full Text] [Related]
7. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome.
Esteva-Font C; Baccaro ME; Fernández-Llama P; Sans L; Guevara M; Ars E; Jiménez W; Arroyo V; Ballarín JA; Ginès P
Hepatology; 2006 Dec; 44(6):1555-63. PubMed ID: 17133493
[TBL] [Abstract][Full Text] [Related]
8. Urinary excretion of 6-keto-prostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome).
Rimola A; Ginés P; Arroyo V; Camps J; Pérez-Ayuso RM; Quintero E; Gaya J; Rivera F; Rodés J
J Hepatol; 1986; 3(1):111-7. PubMed ID: 3462243
[TBL] [Abstract][Full Text] [Related]
9. Urinary excretion of prostaglandins and thromboxanes in the hepatorenal syndrome.
Kronborg IJ; Radvan G; Zipser RD
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():539-42. PubMed ID: 6221576
[No Abstract] [Full Text] [Related]
10. Volume-induced natriuresis in healthy women: renal metabolism of prostacyclin and thromboxane, and physiological role of prostanoids.
Agnoli GC; Borgatti R; Cacciari M; Lenzi P; Marinelli M; Stipo L
Prostaglandins Leukot Essent Fatty Acids; 2001 Feb; 64(2):95-103. PubMed ID: 11237476
[TBL] [Abstract][Full Text] [Related]
11. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P
Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome.
Zipser RD; Kronborg I; Rector W; Reynolds T; Daskalopoulos G
Gastroenterology; 1984 Dec; 87(6):1228-32. PubMed ID: 6593268
[TBL] [Abstract][Full Text] [Related]
13. Lack of renal effects of fish oil administration in patients with advanced cirrhosis and impaired glomerular filtration.
Badalamenti S; Salerno F; Salmeron JM; Lorenzano E; Rimola A; Ginés P; Jimenez W; Graziani G; Arroyo V; Rodes J; Ponticelli C
Hepatology; 1997 Feb; 25(2):313-6. PubMed ID: 9021940
[TBL] [Abstract][Full Text] [Related]
14. Urinary gastrin output and serum gastrin in patients with liver cirrhosis. Urinary gastrin output in cirrhosis.
Avgerinos A; Dimitriou-Voudri Y; Adamopoulos A; Papadimitriou N; Voudris B; Rekoumis G; Raptis S
Hepatogastroenterology; 1994 Oct; 41(5):445-8. PubMed ID: 7851853
[TBL] [Abstract][Full Text] [Related]
15. Effects of dietary n-3 fatty acid supplementation versus thromboxane synthetase inhibition on gentamicin-induced nephrotoxicosis in healthy male dogs.
Grauer GF; Greco DS; Behrend EN; Fettman MJ; Mani I; Getzy DM; Reinhart GA
Am J Vet Res; 1996 Jun; 57(6):948-56. PubMed ID: 8725828
[TBL] [Abstract][Full Text] [Related]
16. Effects of dietary polyunsaturated fatty acid supplementation in early renal insufficiency in dogs.
Brown SA; Brown CA; Crowell WA; Barsanti JA; Kang CW; Allen T; Cowell C; Finco DR
J Lab Clin Med; 2000 Mar; 135(3):275-86. PubMed ID: 10711867
[TBL] [Abstract][Full Text] [Related]
17. Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis.
Pantaleo P; Marra F; Vizzutti F; Spadoni S; Ciabattoni G; Galli C; La Villa G; Gentilini P; Laffi G
Clin Sci (Lond); 2004 Jan; 106(1):27-34. PubMed ID: 12877651
[TBL] [Abstract][Full Text] [Related]
18. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
Yoshida T; Kameda H; Ichikawa Y; Tojo T; Homma M
J Rheumatol; 1996 Oct; 23(10):1719-24. PubMed ID: 8895147
[TBL] [Abstract][Full Text] [Related]
19. Renal prostaglandins and thromboxane A2 lack a functional significance in the genesis of protein-induced glomerular hyperfiltration in human renal disease.
De Santo NG; Calò L; Coppola S; Anastasio P; Cantaro S; Favaro S; Capasso G; Borsatti A
Nephron; 1993; 63(1):49-53. PubMed ID: 8446251
[TBL] [Abstract][Full Text] [Related]
20. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
Wensing G; Lotterer E; Link I; Hahn EG; Fleig WE
Hepatology; 1997 Nov; 26(5):1149-55. PubMed ID: 9362355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
